Cargando…

Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report

BACKGROUND: NUT midline carcinoma (NMC) is a poorly differentiated squamous cancer with a median survival at less than 7 months. NMC is resistant to conventional chemotherapies and characterized by rearrangement of the NUT gene. CASE PRESENTATION: Here, we described a patient who initially presented...

Descripción completa

Detalles Bibliográficos
Autores principales: Chai, Peiwei, Zhou, Chuandi, Jia, Renbing, Wang, Yefei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942267/
https://www.ncbi.nlm.nih.gov/pubmed/31900183
http://dx.doi.org/10.1186/s13000-019-0922-1
Descripción
Sumario:BACKGROUND: NUT midline carcinoma (NMC) is a poorly differentiated squamous cancer with a median survival at less than 7 months. NMC is resistant to conventional chemotherapies and characterized by rearrangement of the NUT gene. CASE PRESENTATION: Here, we described a patient who initially presented with epiphora, and an orbit involved NMC. In addition, we for the first time demonstrated that local radiotherapy combined with tyrosine kinase inhibitor (TKI) could significantly inhibit tumor progression in orbital involvement by NMC. CONCLUSIONS: Our study for the first time described an orbit involved NMC patient initially presented with epiphora. In addition, we provided an alternative to the management of orbit involved NMC.